1. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update. Allergy. 2014;69:868–887. doi: 10.1111/all.12313
2. Colgecen E, Ozyurt K, Irfan Gul A, Utas S. Evaluation of etiological factors in patients with chronic urticaria. Acta Dermatovenerologica Croatica. 2015;23:36–42
3. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014;73:57–62. doi: 10.1016/j.jdermsci.2013.08.011
4. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. The Journal of Allergy and Clinical Immunology. 2013;132:101–109. doi: 10.1016/j.jaci.2013.05.013
5. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. The New England Journal of Medicine. 2013;368:924. doi: 10.1056/NEJMoa1215372